Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Factor VIII Stories

2012-02-14 06:30:00

NES-ZIONA, Israel, Feb. 14, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor VIIa (Factor VIIa-CTP) in hemophilic mice. The study was designed to measure the potential increase in survival rates, thrombin levels and in vivo recovery of Factor VIIa-CTP when compared with commercially available recombinant Factor VIIa. In vivo recovery is a pharmacokinetic...

2012-02-02 08:45:00

ST. GALLEN, Switzerland, Feb. 2, 2012 /PRNewswire/ -- CSL Behring today announced the results of a Phase I study evaluating recombinant fusion protein linking coagulation Factor IX with albumin (rIX-FP) in patients with severe hemophilia B. Results of the study, which were presented during an oral session at the Gesellscaft fur Thrombose- und Hameostasegorschung (GTH) congress in Switzerland, showed that rIX-FP was well tolerated in all patients and lasted longer in the...

2012-02-02 06:00:00

WAYNE, N.J., Feb. 2, 2012 /PRNewswire/ -- To further its commitment to the hemophilia community, Bayer HealthCare is expanding the Bayer Hemophilia Leadership Development Program (BHLDP) by adding a community element to the internship experience. The 2012 interns selected to participate in this prestigious program will spend five weeks of the eight-week program at a local hemophilia organization. The company is currently seeking applicants who are attending college...

2012-02-01 06:00:00

DUBLIN and RICHMOND, Calif., Feb. 1, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, and Sangamo BioSciences, Inc. (NASDAQ: SGMO), a leader in genome-editing technology, announced today that they have entered into a collaboration and license agreement to develop therapeutics for hemophilia and other monogenic diseases based on Sangamo's zinc finger DNA-binding protein (ZFP) technology. Shire will receive exclusive...

2012-01-12 08:15:00

VIENNA, Jan. 12, 2012 /PRNewswire/ -- CSL Behring has announced that the first site has been initiated in its global phase II/III, multi-center study to evaluate the safety, efficacy and pharmacokinetics of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). The site is located in Vienna, Austria. The prospective, open-label study will enroll adolescents and adults (12 - 65 years) who have hemophilia B. CSL Behring, in collaboration with...

2012-01-05 08:19:00

DEERFIELD, Ill., Jan. 5, 2012 /PRNewswire/ -- Baxter International Inc. today announced the dosing of the first patients in a Phase I clinical trial of its lead investigational candidate, BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein. BAX 855 is based on Baxter's ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] full-length rFVIII molecule and plasma/albumin-free (PAF) manufacturing process. The...

2011-12-22 06:31:00

CAMBRIDGE, Mass., Dec. 22, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration), the only biopharmaceutical company focused exclusively on the development and commercialization of new treatment options for people with hemophilia, announced today that the Company has expanded its leadership team with four key hires. Howard Levy, M.D., Ph.D. has joined Inspiration as Chief Medical Officer; Daniel Regan as Chief Commercial Officer; Nikki Hadas as General...

2011-12-22 06:30:00

CAMBRIDGE, Mass., Dec. 22, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration), the only biopharmaceutical company focused exclusively on the development and commercialization of new treatment options for people with hemophilia, announced today the Company will relocate its corporate headquarters to Cambridge, MA from Laguna Niguel, CA. The move is integral to Inspiration's plan to accommodate its anticipated future staffing and facility needs as the...

2011-12-12 06:30:00

LAGUNA NIGUEL, Calif., Dec. 12, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) has presented key scientific data from the Company's two lead hemophilia development programs - IB1001, a recombinant factor IX (FIX) product, which is in clinical trials for the treatment and prevention of bleeding in individuals with hemophilia B; and OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product, which is being evaluated for the treatment of...

2011-11-29 08:46:00

BEDFORD, Mass., Nov. 29, 2011 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced the release of the new HemosIL von Willebrand Factor Ristocetin Cofactor Activity (VWF: RCo) assay as a European CE IVD Mark product under the European Directive on in vitro Diagnostic Medical Devices. It will be commercialized in Europe and other international regions. This new, fully automated VWF: RCo assay is for use on the ACL TOP® Family of Hemostasis Testing...